Search Results - "Underhill, C.R."

Phase 1 clinical trial of marizomib (MRZ, NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 (NCT00629473) final results by Harrison, S.J, Catley, L, Price, T, Millward, M.J, Padrik, P, Underhill, C.R, Cannell, P.K, Burrows, F.J, Reich, S.D, Trikha, M, Spencer, A

Get full text

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601) by Gedye, C., Harris, C.A., Stockler, M.R., Morris, M., Ferguson, T., Goh, J.C.H., Martin, A., Underhill, C.R., Pook, D., Krieger, L.E.M., Kichenadasse, G., Joshi, A.J., Subramaniam, S., Zebic, D.S., Zhang, A., Joshua, A.M., Toner, G.C., Vasey, P.A., Prithviraj, P., Davis, I.D.

Get full text

1614P Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake by Nguyen, M., Bain, N.T., Grech, L., Kwok, A., Hamad, N., Tognela, A., Chan, B.A., Nott, L.M., Harris, S., Chau, N.M.H., Underhill, C.R., Day, D., McCartney, A., Webber, K., Segelov, E.

Get full text

157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers by Mislang, A.R.A., Coward, J., Cooper, A., Underhill, C.R., Zheng, Y., Xu, N., Xiao, C., Jin, X., Li, B., Wang, M., Kwek, K.Y., Xia, D., Xia, Y., Prawira, A.

Get full text

550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study by Xu, R-H., Xu, Y., Yan, D., Munster, P., Ruan, D., Deng, Y., Pan, H., Underhill, C.R., Richardson, G., Nordman, I., Lee, K-W., Wei, S., Li, X., Shan, J., Han, G., Henderson, S., Xie, X., Xiang, Z., Shi, Z., Zhang, L.

Get full text

380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial by Day, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C.R., Nott, L.M., van Hazel, G., van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H.C., Jones, F., Segelov, E.

Get full text

Inequity in rural cancer survival in Australia is not an insurmountable problem by Underhill, Craig R, Goldstein, David, Grogan, Paul B

Get full text

564 Lithium gammolinolenate (LiGLA)- a novel outpatient treatment for nonresectable pancreatic carcinoma (PC) by Underhill, C.R., Harper, P.G., Highley, M.S., Ahem, J., Barker, S.C., Wright, C.J., Ahmed, A., Houston, S.J., Miles, D.W., Larvin, M., Mason, R.C.

“…LiGLA, a lithium salt of an essential fatty acid, has cytotoxicity in vitro and in vivo against a number of tumour types; a phase II trial has shown median…”
Get full text